India is accelerating its efforts to emerge as a global leader in diabetes research, with more than a dozen projects exploring next-generation therapies, genetic interventions and innovative prevention strategies. These initiatives include research on GLP-1-producing engineered bacteria, gut microbiome therapies, genetic treatments and precision medicine, according to Union Minister of State for Science and Technology Jitendra Singh.
The Department of Biotechnology (DBT), along with research institutions under the Council of Scientific and Industrial Research (CSIR), is supporting several of these projects, reflecting India’s growing focus on indigenous healthcare innovation.
Addressing the inaugural ceremony of RSSDI 2026 in Bengaluru, Singh highlighted India’s large population and genetic diversity as major advantages for diabetes research. He also stressed the need to address rising obesity and diabetes among young people, stating that prevention must become a national responsibility.
Engineered Bacteria and GLP-1 Research Offer New Possibilities
Among the key research initiatives is an Indo-Danish study investigating gut microbiome changes in people with prediabetes and diabetes to understand their influence on metabolic health.
Another DBT-supported project is developing genetically engineered E. coli Nissle 1917 bacteria capable of producing GLP-1, a hormone involved in blood glucose regulation. The approach could potentially enable probiotic-based delivery of therapeutic molecules. Researchers at BRIC-THSTI are also exploring GLP-1 analogue production through gut-associated bacteria.
Research Focuses on Early Diabetes Prevention
Researchers are examining ways to reduce diabetes risk from pregnancy through childhood. These studies investigate childhood blood glucose, blood pressure and adiposity, while the EINSTEIN study in rural Mysuru aims to generate evidence for stronger preventive healthcare strategies.
Other projects are exploring how maternal nutrition during pregnancy influences the metabolic health of children, highlighting the importance of early intervention.
Biomarkers and Genetic Research Advance Precision Medicine
Several research initiatives are investigating molecular pathways and biomarkers to improve diabetes prediction and treatment. These include studies using exosomal profiling and metabolomics to identify Type 2 diabetes risk among women with a history of gestational diabetes.
Scientists are also examining the relationship between Type 2 diabetes and metabolic dysfunction-associated fatty liver disease (MAFLD), alongside potential therapeutic targets involving S100A6, SIRT1 and insulin signalling.
Additionally, research into macrophage Gi signalling and arachidonic acid could offer new insights into managing obesity, insulin resistance and diabetes-related complications.
Temperature-Resilient and Oral Insulin Under Development
India is exploring temperature-resilient insulin to address storage and transportation challenges, particularly in difficult settings. Startups are also investigating oral insulin as an alternative delivery approach.
Furthermore, indigenous biosimilar development, including liraglutide and insulin Lispro, could support more affordable diabetes treatment options.
Minister Highlights India’s Genetic Advantage and Need for Prevention
Singh highlighted the India Genome Study, which covered 10,000 individuals across 84 population groups, as an important resource for understanding genetic variations and developing personalised healthcare solutions.
He also warned against health misinformation, unscientific dietary advice and the unprescribed use of weight-loss drugs, urging healthcare professionals to promote evidence-based information.
Emphasising the importance of protecting India’s younger population, Singh said preventing obesity and diabetes is essential to achieving Viksit Bharat by 2047. He called for stronger collaboration among research institutions, medical professionals, startups and policymakers to accelerate affordable treatments and preventive healthcare solutions, as reported by Indian Pharma Post.



















